IL3RA and acute myeloid leukemia: An early phase pilot study, sponsored by the University of Pennsylvania, investigating an anti-CD123-CD3-4-1BB CAR in five R/R AML patients, was interrupted for lack of efficacy and on target/off tumor adverse events [61].